Valuation
- Market cap
- 1,168,495,000
- Revenue TTM
- $42,730,000
- Net income TTM
- $-204,380,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -478.31%
- Debt to equity
- 0.00
Trading
- Volume
- 4,553,224
- Avg volume
- 2,915,306
- Day's range
- $5.92 – $6.15
- Shares out
- 197,048,000
- Stochastic %K
- 84%
- Beta
- -1.26
- Analysts
- Strong Sell
- Price target
- $20.81
Company profile
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 anti...
Show more
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 949 2900
- Website
- https://wavelifesciences.com
- Address
- 733 Concord Avenue, Cambridge, United States
Latest news
No headlines yet.
